Bayer meets Schering target

June 2006
ICIS Chemical Business;6/19/2006, Vol. 1 Issue 24, p10
Trade Publication
The article reports on the success of Bayer in meeting its target of acquiring at least 75% of German pharmaceutical group Schering. At an estimated € 17bn, the Schering buy will cost Bayer € 500m more than first calculated. The last-minute reentry of German pharma and chemicals group Merck into the race forced the stakes up to € 89/ share from € 86.


Related Articles

  • News in brief.  // Nature Reviews Drug Discovery;Jul2006, Vol. 5 Issue 7, p530 

    The article presents news briefs related to the recent developments in the pharmaceutical industry. Merck & Co. Inc.'s cervical cancer vaccine Gardasil has successfully passed the regulatory and scientific hurdles, but other hurdles might prove to be more problematic. Studies have shown that the...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Aug2006, Vol. 5 Issue 8, p3 

    The article reports on the developments in the pharmaceutical industry worldwide. Bayer AG has acquired Schering AG at approximately €17 billion. The U.S. Food & Drug Administration has approved Gardasil, a cervical cancer vaccine, from Merck & Co. Inc. Abbott Laboratories Inc. and...

  • Too little, too late? Abbot, Alison // Nature;3/30/2006, Vol. 440 Issue 7084, p603 

    The article examines the merger activity in the pharmaceutical industry in Germany. It details Bayer AG's offer to buy Schering AG. According to pharmaceutical analysts, the merger will affect mid-sized drug companies. There are three ways for these companies to respond according to a report...

  • Bayer-Schering combo a better fit? Mirasol, Feliza // Chemical Market Reporter;4/3/2006, Vol. 269 Issue 13, p22 

    The article reports on Bayer AG's bid to take over Schering AG which is expected to result in a leading specialized global pharmaceutical entity. The acquisition could bolster Bayer's HealthCare division, particularly in the area of pharmaceutical specialty products. Bayer's bid trumped Merck...

  • Schering improves as Bayer files bid. Robinson, Simon // ICIS Chemical Business;5/1/2006, Vol. 1 Issue 17, p11 

    The article reports on the strong results presented by Schering going into the planned takeover by Bayer. The Berlin group said growth drivers were the multiple sclerosis drug Betaferon and the oral contraceptive Yasmin. The strongest improvement was seen in gynecology and andrology. Bayer has...

  • Bayer Acquisition. S. H. // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p26 

    The article reports that Bayer will acquire Schering AG, a German pharmaceutical company. According to the article, the acquisition deal which is estimated to be worth $19.8 billion, was a response to a hostile bid from Merck KGaA. It is expected that the merger will result in 6,000 job losses...

  • Bayer Clinches Acquisition of Schering.  // Chemical Week;6/28/2006, Vol. 168 Issue 22, p5 

    The article reports on the acquisition of Schering by Bayer as of June 28, 2006. Shareholders representing majority of Schering's equity had accepted Bayer's offer by June 20. Bayer will merge its pharmaceuticals business with Schering to form Bayer Schering Pharma in Berlin, Germany. Its...

  • Pharma troubles are bitter pill. Williams, Dede // ICIS Chemical Business;3/17/2008, Vol. 273 Issue 11, p12 

    The article presents information on several problems faced by Bayer AG, a pharmaceutical firm headquartered in Leverkusen, Germany. It states that even though the firm seems to have revitalized its healthcare franchise Bayer HealthCare AG with the acquisition of pharma research firm Schering AG...

  • Bayer to acquire Merck & Co.'s consumer-care business for $14.2 billion.  // Chemical Week;5/5/2014, Vol. 175 Issue 13, p6 

    The article discusses an announcement made by the chemical and pharmaceutical company Bayer of its plans to acquire the consumer-care business of the pharmaceutical company Merck & Co as of May 5, 2014, making Bayer the second largest company in over-the-counter products after Johnson & Johnson.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics